Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Betaine-anhydrous; Cystadan; Cystadane; RM-003

Latest Information Update: 17 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orphan Medical
  • Developer Recordati; ReqMed
  • Class Quaternary ammonium compounds; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Methyltransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Homocystinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Homocystinuria
  • No development reported Infantile Refsum disease; Peroxisomal disorders; Zellweger syndrome

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 Apr 2017 Recordati Rare Diseases acquires North American marketing rights to Betaine anhydrous from Recordati
  • 03 Jun 2016 No development reported - Phase-III for Zellweger syndrome, Peroxisomal disorders and Infantile Refsum disease in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top